NEW DELHI : The recent executive orders on pharma issued by President Donald Trump are expected to create significant challenges for Indian pharmaceutical companies, especially those operating in the U.S. generic drug market, according to a report by Nuvama Research.
These policy moves aim to prioritize domestic manufacturing of pharmaceuticals in the United States and could reshape global drug supply chains if implemented strictly.
The report said “The new development, if fully implemented, can disrupt and reshape global pharma . . .
Disclaimer: This information has been collected through secondary research and Daily Shipping Times is not responsible for any errors in the same.
You cannot copy content of this page
